John Newman
Stock Analyst at Canaccord Genuity
(2.07)
# 3,021
Out of 5,138 analysts
89
Total ratings
44.16%
Success rate
-7.33%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATRA Atara Biotherapeutics | Downgrades: Hold | $25 → $6 | $4.32 | +38.89% | 7 | Jan 13, 2026 | |
| ACET Adicet Bio | Maintains: Buy | $128 → $18 | $7.90 | +127.85% | 7 | Jan 6, 2026 | |
| ACLX Arcellx | Maintains: Buy | $130 | $72.17 | +80.13% | 10 | Dec 8, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $850 → $1,057 | $733.78 | +44.05% | 20 | Dec 4, 2025 | |
| CMPX Compass Therapeutics | Initiates: Buy | $10 | $5.71 | +75.13% | 1 | Dec 3, 2025 | |
| NUVL Nuvalent | Initiates: Buy | $126 | $105.93 | +18.95% | 1 | Nov 12, 2025 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $10.19 | +106.08% | 2 | Oct 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $14 → $22 | $15.06 | +46.08% | 10 | Sep 24, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $1.57 | +791.72% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $105.56 | +62.41% | 8 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.12 | +277.36% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $25 | $5.92 | +322.30% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $7.23 | +494.74% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.99 | +404.74% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $26.68 | +64.92% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $15.62 | +143.28% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $4.75 | +468.42% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $14.79 | - | 1 | Sep 13, 2017 |
Atara Biotherapeutics
Jan 13, 2026
Downgrades: Hold
Price Target: $25 → $6
Current: $4.32
Upside: +38.89%
Adicet Bio
Jan 6, 2026
Maintains: Buy
Price Target: $128 → $18
Current: $7.90
Upside: +127.85%
Arcellx
Dec 8, 2025
Maintains: Buy
Price Target: $130
Current: $72.17
Upside: +80.13%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Buy
Price Target: $850 → $1,057
Current: $733.78
Upside: +44.05%
Compass Therapeutics
Dec 3, 2025
Initiates: Buy
Price Target: $10
Current: $5.71
Upside: +75.13%
Nuvalent
Nov 12, 2025
Initiates: Buy
Price Target: $126
Current: $105.93
Upside: +18.95%
Delcath Systems
Oct 21, 2025
Maintains: Buy
Price Target: $21
Current: $10.19
Upside: +106.08%
Seres Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $14 → $22
Current: $15.06
Upside: +46.08%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $1.57
Upside: +791.72%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $105.56
Upside: +62.41%
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $2.12
Upside: +277.36%
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $5.92
Upside: +322.30%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $7.23
Upside: +494.74%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $0.99
Upside: +404.74%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $26.68
Upside: +64.92%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $15.62
Upside: +143.28%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $4.75
Upside: +468.42%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $14.79
Upside: -